About us Leadership History News Clinical Trials Publications Contact us History 2013 Founded by Amir Jafri January 2014 Terumo BCT, an industry-leading manufacturer of therapeutic apheresis equipment, and Immunicom enter into a strategic partnership May 2014 Start of pre-clinical canine trial December 2015 Completed a $5.5M Series A Preferred Stock financing February 2016 The pre-clinical canine cancer trial ended, achieving 300 Immunopheresis treatments. Overall, 50-60% of the canine patients treated were observed to have either a stable disease or partial response. One canine experienced a complete response with clearance of metastases. December 2017 University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology May 2018 The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer August 2018 Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic June 2019 First patient enrolled in a multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis as a treatment for patients with triple negative breast cancer July 2019 Immunicom hosted the First Annual Global Immunopheresis Conference in Krakow, Poland May 2020 The ImmunopheresisTM LW-02 column received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory triple negative breast cancer (TNBC) July 2020 First patient enrolled in a clinical trial at Sheba Medical Center to investigate the outcomes of ImmunopheresisTM as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, triple negative breast cancer, renal cell carcinoma and non-small cell lung cancer Get in touch today Let’s talk about what we can achieve together Contact us Learn more about our team Who are we Immunicom Inc. HEADQUARTERS San Diego, CA RESOURCES Terms of Use Privacy policy GET IN TOUCH Contact us Newsletter Subscription Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. © 2021 — Immunicom, Inc. All Rights Reserved. We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics. Cookie settings Accept all